{
  "id": "63eeeaaaf36125a426000004",
  "type": "factoid",
  "question": "Beremagene Geperpavec is tested for which disease?",
  "ideal_answer": "Beremagene Geperpavec was tested for recessive dystrophic epidermolysis bullosa.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35347281"
  ],
  "snippets": [
    {
      "text": "Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1, the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35347281",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "recessive dystrophic epidermolysis bullosa"
}